ConductScience.org, home

Comparison · NCT02108171-ff26cf1e

Dexmedetomidine vs Placebo: Patients With Postoperative Nausea in Two Groups

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Dexmedetomidine vs Placebo: Patients With Postoperative Nausea in Two Groups. Trial comparisons, record NCT02108171-ff26cf1e. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02108171-ff26cf1e

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.0250.004430.129wilson
Risk in group 20.07320.02520.194wilson
Risk difference, group 1 minus group 2-0.0482-0.1710.0662newcombe hybrid score
Risk ratio, group 1 over group 20.3420.03713.15log
Odds ratio, group 1 over group 20.3250.03233.26log
Number needed to treat, for one fewer participant with the outcome on Dexmedetomidine than on Placebo20.8from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Dexmedetomidine
intranasal dexmedetomidine~Dexmedetomidine: intranasal dexmedetomidine 1μg.kg-1,0.9% saline was added to make a final volume of 1 mL.all patients received intranasal medication at approximately 45-60 min before induction of anesthesia.
140OG000
Group 2Placebointranasal saline~placebo: 0.9% saline 1 mL all patients received intranasal medication at approximately 45-60 min before induction of anesthesia.341OG001

Outcome

Type
OTHER_PRE_SPECIFIED
Title
Patients With Postoperative Nausea in Two Groups
Description
Patients With postoperative nausea in Two Groups. Nausea or vomiting was treated with 4 mg of intravenous ondansetron.
Time frame
1 day
Population

Source ClinicalTrials.gov

Trial

Title
Intranasal Dexmedetomidine Premedication
NCT number
NCT02108171
Phases
NA
Conditions
Benign Neoplasm of Vocal Fold - Glottis
Interventions
Dexmedetomidine, placebo
Lead sponsor
Guangzhou First People's Hospital
Results first posted
2016-03-14

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02108171-ff26cf1e